Toolkit

Email Alert

Sign up to join Advicenne’s Press Releases diffusion list

Contacts

Advicenne
2, rue Briçonnet, 30 000 Nîmes, France
+33 4 66 05 54 20
investors@advicenne.com

U.S. Investor Relations
Rx Communications Group, LLC
555 Madison Ave,
New York, NY 10022, USA
+001 917-322-2216
Melody Carey mcarey@rxir.comPaula Schwartz pschwartz@rxir.com

Financial Communications
NewCap
Emmanuel Huynh & Alexia Faure
+33 1 44 71 94 94
advicenne@newcap.eu

Stock information

Advicenne shares were listed on Euronext Paris on December 6, 2017 and on Euronext Brussels on June 12, 2019. 

ISIN code: FR0013296746

Ticker: ADVIC

Number of outstanding shares: 8 062 344

Eligible for PEA and PEA-PME

Ownership Structure on January 5, 2018

Ownership Structure on January 5, 2018 Diagram
Advicenne's, company dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology.

Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.

© 2019 Advicenne